Standard
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer : results from a randomized phase III trial from the Danish breast cancer cooperative group. / Jørgensen, Charlotte Levin Tykjær; Bjerre, Christina Annette; Ejlertsen, Bent Laursen; Bjerre, Karsten D.; Balslev, Eva; Bartels, Annette; Brünner, Nils; Nielsen, Dorte L.
In:
B M C Cancer, Vol. 14, 360, 2014.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Jørgensen, CLT, Bjerre, CA
, Ejlertsen, BL, Bjerre, KD, Balslev, E
, Bartels, A, Brünner, N & Nielsen, DL 2014, '
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group',
B M C Cancer, vol. 14, 360.
https://doi.org/10.1186/1471-2407-14-360APA
Jørgensen, C. L. T., Bjerre, C. A.
, Ejlertsen, B. L., Bjerre, K. D., Balslev, E.
, Bartels, A., Brünner, N., & Nielsen, D. L. (2014).
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group.
B M C Cancer,
14, [360].
https://doi.org/10.1186/1471-2407-14-360Vancouver
Jørgensen CLT, Bjerre CA
, Ejlertsen BL, Bjerre KD, Balslev E
, Bartels A et al.
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group.
B M C Cancer. 2014;14. 360.
https://doi.org/10.1186/1471-2407-14-360Author
Jørgensen, Charlotte Levin Tykjær ; Bjerre, Christina Annette ; Ejlertsen, Bent Laursen ; Bjerre, Karsten D. ; Balslev, Eva ; Bartels, Annette ; Brünner, Nils ; Nielsen, Dorte L. / TIMP-1 and responsiveness to gemcitabine in advanced breast cancer : results from a randomized phase III trial from the Danish breast cancer cooperative group. In: B M C Cancer. 2014 ; Vol. 14.
Bibtex
@article{07ba8e8fd6e74bc69030267929e2173d,
title = "TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group",
keywords = "TIMP-1, Gemcitabine, Docetaxel, Breast cancer, Prediction, Prognosis",
author = "J{\o}rgensen, {Charlotte Levin Tykj{\ae}r} and Bjerre, {Christina Annette} and Ejlertsen, {Bent Laursen} and Bjerre, {Karsten D.} and Eva Balslev and Annette Bartels and Nils Br{\"u}nner and Nielsen, {Dorte L.}",
year = "2014",
doi = "10.1186/1471-2407-14-360",
language = "English",
volume = "14",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
}
RIS
TY - JOUR
T1 - TIMP-1 and responsiveness to gemcitabine in advanced breast cancer
T2 - results from a randomized phase III trial from the Danish breast cancer cooperative group
AU - Jørgensen, Charlotte Levin Tykjær
AU - Bjerre, Christina Annette
AU - Ejlertsen, Bent Laursen
AU - Bjerre, Karsten D.
AU - Balslev, Eva
AU - Bartels, Annette
AU - Brünner, Nils
AU - Nielsen, Dorte L.
PY - 2014
Y1 - 2014
KW - TIMP-1
KW - Gemcitabine
KW - Docetaxel
KW - Breast cancer
KW - Prediction
KW - Prognosis
U2 - 10.1186/1471-2407-14-360
DO - 10.1186/1471-2407-14-360
M3 - Journal article
C2 - 24884504
VL - 14
JO - B M C Cancer
JF - B M C Cancer
SN - 1471-2407
M1 - 360
ER -
